XTR024

XTR024 is an innovative radiopharmaceutical candidate currently in the preclinical development stage by Sinotau Pharmaceutical Group. It is specifically being developed for the theranostic management (imaging and therapy) of neuroendocrine tumors (NETs). As a radioligand therapy, XTR024 is designed to target specific biomarkers overexpressed on the surface of neuroendocrine tumor cells, typically somatostatin receptors (SSTR). By conjugating a targeting ligand to a radioactive isotope, the agent facilitates the precise delivery of radiation for either diagnostic visualization via PET/SPECT imaging or targeted radionuclide therapy to destroy malignant tissues. The program is part of Sinotau's broader pipeline of innovative radiopharmaceuticals focused on oncology and neurodegenerative diseases.